Randall Reed, MD
Rheumatology · Indianapolis, INNPI 1619925757
Payments from drug & device makers
Across 254 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- UCB, Inc.$558
- Johnson & Johnson$525
- Boehringer Ingelheim$426
- AstraZeneca$326
- plus $3K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $1,114 |
| Amgen(2 entities) | 46 | $1,112 |
| UCB, Inc. | 16 | $558 |
| Johnson & Johnson | 16 | $525 |
| Boehringer Ingelheim | 7 | $426 |
| AstraZeneca(2 entities) | 10 | $326 |
| Novartis | 15 | $322 |
| Bristol Myers Squibb | 7 | $295 |
| Mallinckrodt Hospital Products Inc. | 5 | $272 |
| Lilly USA, LLC | 10 | $268 |
| Pfizer | 16 | $261 |
| E.r. Squibb & Sons, L.L.C. | 14 | $260 |
| Genentech USA, Inc. | 8 | $236 |
| Janssen Scientific Affairs, LLC | 3 | $227 |
| GSK | 8 | $211 |
| Sobi, Inc | 2 | $165 |
| Radius Health, Inc. | 7 | $165 |
| Regeneron Healthcare Solutions, Inc. | 6 | $128 |
| Mallinckrodt Enterprises LLC | 4 | $93 |
| Aurinia Pharma U.S., Inc. | 3 | $67 |
| Kyowa Kirin, Inc. | 2 | $56 |
| Merck | 3 | $40 |
| Octapharma USA, Inc. | 1 | $25 |
| Medexus Pharma, Inc. | 2 | $24 |
| Sanofi | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $23 |
| Organon | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Celltrion USA Inc. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Gilead | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $12 |
| Fidia Pharma USA Inc. | 1 | $3 |
How this compares
$7,358 in reported general payments places this provider in the 65th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Indianapolis
- David BattIndianapolis$577K
- Douglas SmithIndianapolis$147K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
- Steven HugenbergIndianapolis$50K
- James EhlichIndianapolis$27K
- Christopher WuIndianapolis$26K
- Michael StackIndianapolis$21K
- Methee SrivatanaIndianapolis$10K
- Mary JacobsIndianapolis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.